MedTrace Logo

24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial

NCT04989257 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3488

Last updated 2021-08-04

No results posted yet for this study

Summary

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous coronary intervention with drug-eluting stent implantation

Conditions

  • High Ischemic Risk

Interventions

DRUG

Ticagrelor-based dual-antiplatelet therapy

Aspirin with ticagrelor

DRUG

Clopidogrel-based dual-antiplatelet therapy

Aspirin with clopidogrel

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Byeong-Keuk Kim · Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989257 on ClinicalTrials.gov